These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 34812991)

  • 1. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
    Nath A; Mitra S; Mistry T; Pal R; Nasare VD
    Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
    James N; Owusu E; Rivera G; Bandyopadhyay D
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer.
    Kumari M; Krishnamurthy PT; Sola P
    Curr Cancer Drug Targets; 2020; 20(8):559-572. PubMed ID: 32370716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.
    Nedeljković M; Damjanović A
    Cells; 2019 Aug; 8(9):. PubMed ID: 31443516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
    Jia LY; Shanmugam MK; Sethi G; Bishayee A
    Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
    Ferrari P; Scatena C; Ghilli M; Bargagna I; Lorenzini G; Nicolini A
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.
    Bousquet G; El Bouchtaoui M; Sophie T; Leboeuf C; de Bazelaire C; Ratajczak P; Giacchetti S; de Roquancourt A; Bertheau P; Verneuil L; Feugeas JP; Espié M; Janin A
    Oncotarget; 2017 May; 8(21):35205-35221. PubMed ID: 28445132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
    Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
    Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple negative breast cancer: special histological types and emerging therapeutic methods.
    Cao L; Niu Y
    Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New targets for triple-negative breast cancer.
    Herold CI; Anders CK
    Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.
    Qayoom H; Wani NA; Alshehri B; Mir MA
    Future Oncol; 2021 Nov; 17(31):4185-4206. PubMed ID: 34342489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
    von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
    Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferroptosis as a promising targeted therapy for triple negative breast cancer.
    Mokhtarpour K; Razi S; Rezaei N
    Breast Cancer Res Treat; 2024 Oct; 207(3):497-513. PubMed ID: 38874688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.